Research findings, pricing news, and vendor analysis across the peptide market.
Posts about Tirzepatide
Showing 31 to 55 of 55
Zepbound is still the stronger weight-loss choice for buyers who can tolerate injections and get coverage. Foundayo is the simpler access play if you want a daily pill, lower direct-pay entry pricing, or a CVS Caremark path starting sooner.
Read more →Novi is the cleaner pick if you want low all-in pricing, weekly injections, fast shipping, coaching, and month-to-month flexibility. Shed is the stronger fit if you want more medication formats, a brand-name pathway, unlimited provider visits, Pivot app support, FSA eligibility, and a 10% body-weight-loss guarantee.
Read more →Direct Meds is the stronger fit if you want a simpler clinical GLP-1 path with nurse support, all-in pricing, and fast shipping. Shed is the stronger fit if you want more medication formats, a 10% body-weight-loss guarantee, coaching, unlimited provider appointments, and a brand-name pathway.
Read more →The current evidence does not show a broad human cancer-risk increase from GLP-1 drugs, and some studies suggest lower risk for obesity-related cancers. This explainer separates thyroid-label warnings, pancreatic-cancer fears, observational signals, and what the data cannot prove.
Read more →PeterMD is the stronger fit if you want a broader men's health platform with GLP-1s, TRT, ED, hair loss, and longevity options under one account. Medvi is the stronger fit if you want a weight-loss-focused GLP-1 program with lower semaglutide entry pricing, coaching, nutrition support, and a clearer support-heavy path.
Read more →Novi is the better fit if you want the lowest all-in compounded GLP-1 pricing with coaching and fast shipping. Direct Meds is the better fit if you want a more clinical checkout, doctor review, 503A pharmacy claims, and clearer refill support at a higher monthly price.
Read more →Novi is the better fit if you want the lower all-in compounded GLP-1 entry price, simple month-to-month access, and free 2-day shipping. Medvi is the better fit if you want a more structured program with clinician review, 1:1 guidance, metabolic reporting, coaching, tablets, and brand-name membership routes.
Read more →Peter MD is better if you want GLP-1 access alongside men's health add-ons like TRT, ED medication, hair loss, and longevity products. SkinnyRx is better if you want lower-friction compounded semaglutide or tirzepatide access with clear medication-specific plans.
Read more →Peter MD is better if you want GLP-1 access bundled with men's health options like TRT, ED, hair loss, and longevity care. Direct Meds is better if you want a weight-loss-focused GLP-1 program with nurse support and transparent monthly pricing.
Read more →Most weight-loss peptide stacks sold online have zero combination evidence. This guide ranks popular combinations from RCT-backed co-formulations to community protocols with no human data.
Read more →Direct Meds is the stronger pick if you want nurse support and a more guided GLP-1 program. Breeze Meds is better if you want pay-as-you-go flexibility, no subscription lock-in, and FSA/HSA-friendly ordering.
Read more →Medvi is the better fit if you want coaching, dietitian-oriented support, and more structured GLP-1 care. Breeze Meds is the better fit if you want pay-as-you-go flexibility, FSA/HSA eligibility, and oral compounded options without subscription lock-in.
Read more →GLP-1 drugs can slow stomach emptying, which may change how some oral medicines are absorbed. The clearest contraception warning is for tirzepatide: use non-oral contraception or add a barrier method for 4 weeks after starting and after each dose increase.
Read more →CVS Caremark says Zepbound will return to its commercial formularies as an additional preferred option on October 1, 2026, while Lilly's oral GLP-1 Foundayo gets a June 1 coverage path where plans approve it. This guide explains what the change does and does not mean, how to check your own benefits, and when cash-pay or telehealth alternatives still matter.
Read more →GLP-1 medications mostly reduce fat mass, but clinical body-composition substudies show some lean mass loss is real. The practical answer is not panic, it is protein, resistance training, slower loss when appropriate, and tracking strength, not just scale weight.
Read more →GLP-1s work without strict dieting — but the research shows that adding protein and resistance training dramatically improves results and prevents muscle loss.
Read more →PCOS affects 1 in 10 women and is driven by insulin resistance. GLP-1 medications target that root cause — and the early research is promising.
Read more →One targets GLP-1 receptors. The other targets GLP-1 and GIP. Clinical trials show tirzepatide edges out semaglutide on weight loss — but the full picture is more nuanced.
Read more →Compounded GLP-1s cost a fraction of brand-name Wegovy or Zepbound. But are they the same drug? An honest breakdown of 503A vs 503B pharmacies, what's identical, what's different, and how to decide.
Read more →Starting Ozempic, Wegovy, or Mounjaro and wondering about drinking? Research shows GLP-1s significantly reduce alcohol cravings — but also change your tolerance in ways that matter practically.
Read more →Up to 70% of GLP-1 patients experience side effects — but most are manageable and temporary. This evidence-based guide covers what to expect at each phase of treatment and practical strategies for every common side effect.
Read more →Most people regain two-thirds of their lost weight within a year of stopping GLP-1 medications. Here's what the clinical trials show, why it happens biologically, and practical strategies to minimize regain.
Read more →New research from the Technical University of Munich and Harvard Medical School reveals that semaglutide and tirzepatide don't just promote weight loss — they appear to fundamentally reshape the body's metabolic and inflammatory pathways in ways researchers didn't fully anticipate.
Read more →New research from the University of Eastern Finland has found that semaglutide (Ozempic/Wegovy) is associated with significantly reduced rates of depression, anxiety, and substance use disorders — adding to a growing body of evidence that GLP-1 drugs do far more than cause weight loss.
Read more →The Trump administration announced deals with Eli Lilly and Novo Nordisk to significantly reduce the cost of weight loss medications through TrumpRx. Here's what we know and what it means for people taking semaglutide or tirzepatide.
Read more →STOP PIECING IT TOGETHER
We wrote the shortcut: five books, 55 compounds, every claim graded by the strength of the real evidence. No hype, no gatekeeping, and free updates for life whenever the market shifts. Most readers say it replaces months of forum digging.
